Interference No. 104,436 Paper 98
Shyamala v. Hillman Page 2
[21 Hillman identifies the protein as guanosine monophosphate reductase as shown in Hillman's SEQ
ID. NO: 1. - : :
[3] Count 2 is the sole count (Paper 72):
A composition according to claim I of 5,756,332
- OR
A composition according to claim I of 09/007,306.
[4] Claim I of Hillman's 332 patent is:
An isolated and purified polynucleotide sequence encoding guanosine
monophosphate reductase having the amino acid sequence of SEQ ID NO: I or an
amino acid sequence that is at least 95% homologous in sequence to the amino
acid sequence of SEQ ID NO: I and having guanosine monophosphate reductase
activity.
[51 Claim I of Hillman's 306 application is:
A substantially purified guanosine monophosphate reductase comprising the
amino acid sequence of SEQ ID NO: I or enzymatically active fragments thereof.
[6] Hillman's SEQ ID NO: I is reproduced in the appendix to this decision.
[7] Shyarnala's claims 1-3, 4, 5, 6, 9, and 10 of its 08/886,572 application correspond to Count 2.
[8] Hillman's claims 1, 2, and 4-9 of its 332 patent and claims I and I I of its 306 application
correspond to Count 2
191 Hillman has been accorded a benefit date of 26 December 1996 for its constructive reduction to
practice of an embodiment within the scope of Count 2.
[10] Shyamala, has been accorded a benefit date of I July 1997 for its constructive reduction to
practice of an embodiment within the scope of Count 2.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007